975 related articles for article (PubMed ID: 3260908)
21. Requirements for the generation of a Lyt-2+ T-cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-cells.
Kern DE; Klarnet JP; Cheever MA; Greenberg PD
Cancer Res; 1990 Oct; 50(19):6256-63. PubMed ID: 2144789
[TBL] [Abstract][Full Text] [Related]
22. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
23. Murine interstitial nephritis. IV. Long-term cultured L3T4+ T cell lines transfer delayed expression of disease as I-A-restricted inducers of the effector T cell repertoire.
Mann R; Zakheim B; Clayman M; McCafferty E; Michaud L; Neilson EG
J Immunol; 1985 Jul; 135(1):286-93. PubMed ID: 2582035
[TBL] [Abstract][Full Text] [Related]
24. Requirements for T cell recognition and elimination of retrovirally-transformed cells.
Greenberg P; Klarnet J; Kern D; Okuno K; Riddell S; Cheever M
Princess Takamatsu Symp; 1988; 19():287-301. PubMed ID: 2479634
[TBL] [Abstract][Full Text] [Related]
25. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
26. Do L3T4+ T cells act as effector cells in protection against influenza virus infection.
Lightman S; Cobbold S; Waldmann H; Askonas BA
Immunology; 1987 Sep; 62(1):139-44. PubMed ID: 2820868
[TBL] [Abstract][Full Text] [Related]
27. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
Kern DE; Klarnet JP; Jensen MC; Greenberg PD
J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
[TBL] [Abstract][Full Text] [Related]
28. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
Shu SY; Chou T; Sakai K
J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
[TBL] [Abstract][Full Text] [Related]
29. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
Sakai K; Chang AE; Shu S
Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
[TBL] [Abstract][Full Text] [Related]
30. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
Evans R; Duffy T
J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
32. Adoptive immunotherapy of newly induced murine sarcomas.
Shu SY; Rosenberg SA
Cancer Res; 1985 Apr; 45(4):1657-62. PubMed ID: 3872168
[TBL] [Abstract][Full Text] [Related]
33. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
[TBL] [Abstract][Full Text] [Related]
34. Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness.
Mizuochi T; Munitz TI; McCarthy SA; Andrysiak PM; Kung J; Gress RE; Singer A
J Immunol; 1986 Nov; 137(9):2740-7. PubMed ID: 2944960
[TBL] [Abstract][Full Text] [Related]
35. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
36. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.
Greenberg PD; Cheever MA
J Biol Response Mod; 1984 Oct; 3(5):455-61. PubMed ID: 6239012
[TBL] [Abstract][Full Text] [Related]
37. Murine interstitial nephritis. III. The selection of phenotypic (Lyt and L3T4) and idiotypic (RE-Id) T cell preferences by genes in Igh-1 and H-2K characterizes the cell-mediated potential for disease expression: susceptible mice provide a unique effector T cell repertoire in response to tubular antigen.
Neilson EG; McCafferty E; Mann R; Michaud L; Clayman M
J Immunol; 1985 Apr; 134(4):2375-82. PubMed ID: 2579142
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to the L3T4 and Lyt-2 molecules interfere with antigen receptor-driven activation of cloned murine T cells.
Moldwin RL; Havran WL; Nau GJ; Lancki DW; Kim DK; Fitch FW
J Immunol; 1987 Aug; 139(3):657-64. PubMed ID: 2955046
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin-dependent helper T cells: studies in the MOPC-315 system suggest a novel surface antigen phenotype.
Rohrer JW; Kemp JD
J Immunol; 1986 Sep; 137(6):1786-92. PubMed ID: 2943802
[TBL] [Abstract][Full Text] [Related]
40. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
Greenberg PD
J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
